Business Wire

CA-INDEX-VENTURES

10.7.2024 06:31:34 CEST | Business Wire | Press release

Share
Index Ventures Announces $2.3bn in New Funds at a Historical Inflection Point for Startups

Index Ventures, a leading global venture capital firm, today announced $2.3 billion in new funds to forge relationships with exceptional entrepreneurs who are creating transformative, category-defining businesses. Combined with Index’s existing $300 million Origin seed fund, Index is deploying $2.6 billion in capital to back founders from seed to IPO. This brings Index’s total capital raised since its founding to $15 billion.

The firm’s fundraise comes at a pivotal moment for the global startup ecosystem. The rise of transformative technologies such as AI, the emergence of tried-and-tested playbooks for hyper-growth companies, and the critical mass of experienced global talent are feeding into and accelerating one another. The result is that entrepreneurs stand at a historical tipping point in which they have unprecedented opportunities to create new, category-defining businesses.

AI opens up entirely new industries for VC investment

“Even though technology has transformed our daily lives, the reality is that it has so much further to go,” said Shardul Shah, partner at Index Ventures. “AI alone will revolutionize virtually every sector of the economy and open up whole industries to venture that have remained virtually untouched. Meanwhile, hundreds of thousands of people have worked in hypergrowth startups globally and can transfer those lessons to the next generation of companies. We’re energized by the unique opportunities that this historical moment presents and excited to partner with founders to solve the world’s trickiest and most consequential problems.”

One global team: from SF to NY, London to Tel Aviv

With its new $800 million venture fund and $1.5 billion growth fund, Index is positioned to be the best long-term partner for entrepreneurs building upon this new foundation wherever they are in the world. Index has a meaningful presence from San Francisco in the West to Tel Aviv in the East – spanning ten time zones and 24 of the world’s 30 most vibrant ecosystems. Established on the West Coast with a portfolio that includes Figma, Discord, Notion, and Roblox, Index has stepped up its US presence with a new New York office. This means it can partner closely with category leaders like Datadog, as well as startups such as Wiz and DataSnipper, using New York as a bridge to help them expand from Europe and Israel across the US. Index has continued strengthening its US leadership by welcoming former Airbnb executive Vlad Loktev to the San Francisco office, who was instrumental in driving Airbnb’s growth and product strategy for over a decade at the company.

Three decades of investing: 108 unicorns, 57 IPOs, 200,000 jobs

Index has a nearly three-decade history of identifying, nurturing, and partnering with visionary founders. Most of these partnerships begin early in a company’s life, at Seed and Series A. Index has invested in 109 companies that reached a $1 billion valuation, 23 that exceeded a $10 billion valuation, and 57 that became publicly traded. The businesses in the Index portfolio have created 200,000 jobs so far and are on track to hire 20,000 more in the next 12 months. Recent highlights from the Index portfolio include:

  • Wiz, the cloud security company in which Index was an early investor, grew to 100x its value within 18 months – becoming the fastest-ever company to hit $100m ARR in that time. Wiz has now reached over $350m in ARR and serves over 40% of the Fortune 100;
  • Scale AI recently raised $1bn and doubled its valuation to $14 billion, and its data foundry powers nearly every leading large language model;
  • DeepL, the language AI company, is transforming the language industry, which is projected to grow to $95.3 billion by 2028. Index led DeepL’s $300M raise at a $2 billion valuation earlier this year;
  • Revolut, the all-in-one finance platform, announced revenues exceeding $2.2 billion for 2023, with record pre-tax profits of $545 million and 45 million customers globally

When Index’s founders succeed, they generate outsized returns for the firm’s limited partners, which include non-profit foundations, educational endowments, healthcare and research institutions, and other impact-oriented organizations.

About Index Ventures

Index Ventures is a global venture capital firm that backs exceptional entrepreneurs. We help founders turn their bold ideas into global businesses and, through the companies they build, have a long-lasting and positive impact on the world around us. Index-backed businesses are supported by an experienced team of investors, strategists, and an extensive global network built over three decades of startup investing. Working side-by-side through the scale-up journey, we forge deep and long-lasting relationships with founders and their teams across many industries and geographies.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240709136755/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye